Abstract
EE284 Cost-Effectiveness of Pembrolizumab in Combination With Chemotherapy As First-Line Treatment of Advanced or Metastatic Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma in France
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have